dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Phase 1CompletedDevelopment Stage
Bioequivalence
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Dec 21, 2015 → Apr 7, 2016
About dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 5/500 mg reference drug (Humacao) + dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon) + dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao) is a phase 1 stage product being developed by AstraZeneca for Bioequivalence. The current trial status is completed. This product is registered under clinical trial identifier NCT02637037. Target conditions include Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects.
What happened to similar drugs?
1 of 1 similar drugs in Bioequivalence were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02637037 | Phase 1 | Completed |
Competing Products
20 competing products in Bioequivalence